Oral propionyl‐l‐carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease

摘要: Objective To ascertain whether oral propionyl-l-carnitine combined with intraplaque verapamil is a useful therapy for advanced or resistant Peyronie's disease. Patients and methods The drugs were assessed in two studies. In the first, 60 patients disease, diagnosed using accepted definitions, randomized subgroups treated infiltration (10 mg weekly 10 weeks) plus 3-month administration of (2 g/day), tamoxifen (40 mg/day) 3 months. second study, 15 disease (progression despite previous therapy) received propionyl-l-carnitine. The differences between variables before after compared analysis variance chi-squared test. Results In first reduction pain was same both subgroups. Propionyl-l-carnitine significantly reduced penile curvature, plaque size, cavernosal artery end-diastolic velocity, need surgery progression, increased International Index Erectile Function score resistivity index arteries. Tamoxifen had none these effects. No drug combination affected peak systolic velocity. Patients receiving no side-effects but those taking did. study modified patterns as patient side-effects. Conclusion The can be considered choice disease.